“$125 million - cost of Priority Review, to save a few months of review time, paid by Sarepta Therapeutics. Paid in 2016 $350 million - priority review paid by AbbVie in 2015”
“$125 million - cost of Priority Review, to save a few months of review time, paid by Sarepta Therapeutics. Paid in 2016 $350 million - priority review paid by AbbVie in 2015”
